Ocular Therapeutix (OCUL) Year-over-year earnings per share growth for the last twelve months

OCUL (Ocular Therapeutix Corp) - company brandmark

Reliance on external contractors for drug production and testing stabilizes dynamics, and quarterly EPS growth has solidified at -11.20. However, regulatory barriers and global supply chain disruption risks are hindering development. To avoid dependence on a single drug, Ocular Therapeutix (OCUL) is expanding its portfolio with implants, which gradually smooths the volatility of financial metrics on the chart.

ocutx.com (OCUL) Earnings per share growth in annualized terms for the last twelve months: for the period 07/04/2022 - 11/18/2026

OCUL (ocutx.com): analytical breakdowns and indicator data

- share price and expert price forecast:
Fundamental valuation:Ocular Therapeutix Inc - OCUL
Finished products of Ocular Therapeutix

Assessing the financial stability of Ocular Therapeutix (OCUL) requires an analysis of net earnings per share dynamics. This metric measures real quarterly income growth, separating actual efficiency from accounting adjustments. By analyzing the quarterly EPS growth profile, an investor can identify the risk of overpaying during an uptrend or a signal of a drawdown during a decline. For biopharmaceuticals, such volatility is mitigated by the low cyclicality of ophthalmological demand. Stable insurance coverage for drugs ensures the predictability of this indicator.

Competitor analysis

Alcon Corp (ALC) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Bausch Health (BLCO)|Year-over-year earnings per share growth for the last twelve months glaukos.com|Apellis Pharmaceuticals (APLS) - Year-over-year net earnings per share change for the last twelve months|Quarterly EPS earnings growth BLTE|HROW (Harrow) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth VRDN (Viridian Corp)|LENZ Corp (LENZ) - Earnings per share growth in annualized terms for the last twelve months|OCS: Year-over-year net earnings per share growth for the last 12 months|Earnings per share growth in annualized terms for the last twelve months eyepointpharma.com|KOD: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Aldeyra Therapeutics (ALDX)|Year-over-year net earnings per share growth for the last 12 months KALA|IRD - Net earnings per share growth for the trailing year|Year-over-year earnings per share growth for the last twelve months okyopharma.com (OKYO)|Quarterly EPS earnings growth Adverum Biotechnologies Inc. (ADVM)|Year-over-year earnings per share growth for the last twelve months outlooktherapeutics.com OTLK|Year-over-year net earnings per share change for the last twelve months Clearside Biomedical, Inc. (CLSD)|NBY - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per one share growth for the last 12 months KPRX (kiorapharma.com)|Alimera Sciences (ALIM) - Year-over-year earnings per share growth for the last twelve months|Eyenovia Inc. - Year-over-year earnings per one share growth for the last 12 months|GHSI (Guardion Health Sciences) - Quarterly EPS earnings growth|Ocuphire Pharma - Year-over-year net earnings per share trend for the last twelve months|Year-over-year net earnings per share growth for the last 12 months OPT (Opthea)